Therapeutic Development 2026: How Cell & Gene Therapy Diverges

Introduction: Why “Therapeutic Development” No Longer Means One Thing

For most of modern pharmaceutical history, “therapeutic development” described a fairly predictable sequence: identify a target, optimize a chemical compound, run randomized trials, file for approval, and manufacture at scale. That model is no longer the default. According to Citeline’s Pharma R&D Annual Review 2026, biotech drugs, including cell and gene therapies, now outnumber small molecules in the active global R&D pipeline for the first time.

That shift has practical consequences. Business development professionals, investors, CDMO and CRO buyers, and regulatory affairs teams increasingly evaluate programs that do not follow the traditional playbook. This article explains how and why cell and gene therapy (CGT) programs diverge from that playbook. It is written for professionals who need to understand these differences, not as an introduction to the science for patients.

The central argument is that CGT diverges from small-molecule and conventional biologic development in five structural areas, not only in mechanism of action:

• Regulatory pathway and review center
• Clinical trial design and evidentiary standards
• Manufacturing economics and CMC complexity
• Long-term monitoring obligations
• Commercial and reimbursement strategy

Existing resources on this topic tend to fall into narrow categories: patient-facing explainers, paywalled market reports, CDMO service marketing, or legal-technical regulatory analyses. This piece pulls those threads into a single comparative framework that readers can use for due diligence, partner selection, and internal strategy discussions.

The 2026 Pipeline Snapshot: Why CGT Demands a Different Framework

The numbers explain why a separate framework is necessary. At the start of 2026, the active global R&D pipeline contained 22,940 drugs. For the first time, biotech modalities surpassed small molecules in that count. Trade press coverage noted that the total pipeline actually contracted slightly year over year, which makes the relative growth of biotech modalities more striking.

Within that broader pipeline, the gene, cell, and RNA therapy segment held 4,487 therapies in development, from preclinical through pre-registration, as of Q2 2026, based on ASGCT and Citeline landscape data. Rare diseases and oncology remain the leading therapeutic areas, both in the overall pipeline and in the clinic.

Among engineered-cell approaches, CAR-T remains the dominant modality, and 81% of CAR-T programs target oncology indications. This concentration matters: much of the field’s clinical, manufacturing, and commercial experience comes from a relatively narrow set of cancer applications.

Regulatory activity is also accelerating. Regulators cleared eight new advanced therapies globally in Q2 2026 alone:

• Five gene therapies
• One RNA therapy
• Two non-genetically modified cell therapies

Those approvals pushed cumulative gene therapy approvals into the mid-40s. A modality that once produced approvals as rare events now generates a steady stream of them, and stakeholders need a reliable way to assess these programs.

Two Regulatory Tracks: CBER/BLA vs. CDER/NDA

The first structural divergence appears inside the U.S. Food and Drug Administration itself. Small-molecule drugs are typically submitted as New Drug Applications (NDAs) and reviewed by the Center for Drug Evaluation and Research (CDER). Most cell and gene therapies, by contrast, are licensed as biologics through Biologics License Applications (BLAs) and reviewed by the Center for Biologics Evaluation and Research (CBER).

This is more than an administrative distinction. Each center has its own review culture, guidance library, staff expertise, and expectations for product characterization. A sponsor moving from small-molecule work into CGT is dealing with a different reviewing body that has different priorities, especially around product identity, potency, and safety over time.

Many CGT sponsors also pursue the Regenerative Medicine Advanced Therapy (RMAT) designation, created under the 21st Century Cures Act in December 2016. RMAT combines the benefits of Fast Track and Breakthrough Therapy designations, and designated programs also become eligible for accelerated approval and priority review. These incentives have no exact equivalent in the standard NDA pathway. For BD and investment teams, whether a program holds RMAT designation is a meaningful signal of regulatory engagement and potential timeline compression.

Clinical Trial Design: Small Populations, Novel Evidence Paths

Traditional small-molecule development relies on large, randomized, placebo-controlled trials. These designs are statistically powerful and widely understood, but they also assume that enough patients exist to enroll meaningful control arms.

CGT often cannot meet that assumption. Many gene therapies target rare or ultra-rare genetic diseases, where the global patient population may be measured in hundreds or even dozens. Recruiting a placebo arm under those conditions may be impossible.

In September 2025, the FDA responded with three coordinated draft guidances written specifically for CGT sponsors:

1. Innovative Designs for Clinical Trials of CGT Products in Small Populations
2. Postapproval Methods to Capture Safety and Efficacy Data
3. Expedited Programs for Regenerative Medicine Therapies for Serious Conditions

Together, these documents establish several alternative evidence paths as acceptable:

• Single-arm trials, in which all participants receive the investigational therapy
• Externally controlled studies, which compare outcomes against natural history data or registry populations
• Bayesian statistical designs, which incorporate prior information to draw conclusions from smaller datasets
• Disease-progression modeling, which projects expected outcomes without treatment as a comparator

Randomization also raises ethical problems in small-N gene therapy trials. As academic work on fairness and protection in these trials has noted, randomized controlled trials are often infeasible for diseases with extremely small patient populations. Assigning a child with a progressive, fatal condition to a placebo arm, when the therapy may be a one-time intervention, is difficult to justify. Regulators and sponsors have therefore adjusted their evidentiary standards.

Implications for investors and BD professionals: Trial design choice is a direct input into diligence. A single-arm study with an external control carries different interpretive risk than a randomized trial, and timeline forecasts depend on whether regulators accept the chosen design. Efficacy data from two CGT programs may not be directly comparable if they rely on different natural history datasets or statistical frameworks. Evaluators should examine the design behind the topline result as closely as the result itself.

The Long-Term Follow-Up Obligation: A Development Timeline With No Small-Molecule Parallel

One of the most consequential and least appreciated differences in CGT development is the long-term follow-up (LTFU) requirement. FDA guidance calls for monitoring gene therapy trial participants for:

• Up to 15 years for products using integrating vectors (such as lentiviral and gammaretroviral vectors) and for genome-editing products
• Up to 5 years for adeno-associated virus (AAV) vectors

The rationale is biological. Therapies that permanently alter a patient’s genome, or insert genetic material that may integrate into host DNA, carry theoretical risks such as delayed adverse events or insertional oncogenesis that may take years to appear.

Traditional small-molecule post-market surveillance has no comparable mandate. Pharmacovigilance for chemical drugs relies largely on adverse event reporting systems and targeted post-marketing studies. It does not require sponsors to track individual trial participants for more than a decade.

The operational implications are substantial. Sponsors must plan for:

• Data infrastructure capable of securely maintaining patient-level records for 15 years
• Patient retention strategies that keep participants engaged as they relocate, age, or change care providers
• Institutional continuity, including what happens to LTFU obligations if the sponsor is acquired, merges, or exits the market

For CDMO and CRO buyers, LTFU capability is a key selection criterion when choosing a clinical partner. For investors, total cost of ownership does not end at approval; a program’s risk profile includes a monitoring commitment that may outlast the original management team.

CMC/Manufacturing Economics: Where CGT Diverges Most Sharply

Chemistry, Manufacturing, and Controls (CMC) is where the gap between CGT and traditional drugs is widest. Small molecules are produced through reproducible chemical synthesis, and a well-characterized process yields identical batches. CGT products depend on living cells, viral vectors, or both. That dependence introduces variability, contamination risk, and batch-to-batch potency problems that chemical manufacturing does not face.

Several specific pressure points define the 2026 manufacturing landscape:

Viral vector capacity. Supply of AAV and lentiviral vectors is widely described as the single biggest bottleneck in the field. Vector batches typically take 3 to 4 weeks to manufacture and another 6 to 8 weeks to test and release before a patient can be dosed. Peer-reviewed literature on AAV manufacturing stresses that the complexity and novelty of these products make robust, scalable processes difficult to establish.

Autologous complexity. Autologous cell therapies, including most approved CAR-T products, are manufactured individually for each patient. Cells are collected, shipped, engineered, expanded, tested, and returned. Each patient effectively represents a separate production run, which makes per-dose cost and turnaround far higher than for mass-produced drugs.

The allogeneic gap. The field is moving toward allogeneic (“off-the-shelf”) and in vivo approaches, which aim to cut turnaround from weeks to hours and to sharply reduce per-dose production costs. Even so, no FDA-approved allogeneic CAR-T product exists as of 2026, despite years of clinical development. That fact shows how much harder manufacturing standardization is for living therapies than for synthesized molecules.

For CDMO buyers, these realities change partner evaluation. Vector capacity, release-testing throughput, chain-of-identity controls, and experience with process comparability matter more than raw reactor volume.

Commercialization & Reimbursement: One-Time Value vs. Chronic Revenue Models

Chronic small-molecule therapies generally follow a recurring-revenue model. Patients take a drug daily or periodically over years, and revenue accrues steadily over the product’s lifetime. Pricing, payer negotiations, and forecasting are all built around that pattern.

CGT often reverses it. Many gene therapies are intended as one-time treatments with potentially curative or durable effects. The commercial model rests on capturing long-term clinical value in a single transaction rather than across years of refills.

Traditional fee-for-service reimbursement systems were not designed for this. They assume predictable, incremental payments for ongoing care. A single high-value treatment concentrates cost into one payment event. Payer budgets, hospital reimbursement mechanics, and risk-sharing arrangements all struggle under that concentration, particularly because the long-term benefit is still being demonstrated.

The Centers for Medicare & Medicaid Services (CMS) Cell and Gene Therapy Access Model is a structural response. The model uses outcomes-based agreements, under which payment terms are linked to whether patients achieve defined clinical results. Casgevy and Lyfgenia, both therapies for sickle cell disease, are prominent examples of products included in this approach. The model shifts some financial risk from payers to manufacturers and ties value to real-world performance.

The key divergence is timing. Traditional drug developers often build go-to-market strategy in late-stage development or near approval. CGT sponsors need to integrate commercial and reimbursement planning from early clinical stages. Endpoint selection, durability measurement, and real-world data collection all affect whether an outcomes-based agreement can be structured later. A program that ignores reimbursement until approval may find its own clinical data unsuitable for the payment models it needs.

Capital Flows and Strategic Positioning in 2026

The funding environment adds context to these structural differences. Biopharma venture funding reached $16.3 billion across 235 rounds in H1 2026, showing continued investor engagement across modalities.

The CGT-specific figures show a sharper turn. In Q2 2026, 20 CGT companies raised $500.4 million in seed and Series A funding, compared with 3 companies raising $197.0 million in Q2 2025. Total CGT dealmaking reached 118 transactions in Q2 2026, up 15% quarter over quarter.

Industry analysts describe 2026 as a “recovery year” for cell and gene therapy. The recovery has a particular character:

• A shift away from platform-driven hype toward asset-level execution
• Investor emphasis on programs with clear clinical and manufacturing paths
• Pipeline expansion beyond oncology and rare disease into autoimmune conditions and ophthalmology

What this signals: For BD professionals, a rebound in early-stage funding means more companies will reach partnering-relevant milestones over the next several years, which could create a crowded field of candidates. Partnership timing may favor those who engage early with assets that show manufacturing readiness. For investors, the momentum is real but selective: capital is flowing toward execution capability rather than broad platform promises.

AI and Automation: Converging Pressure Points Across Both Paradigms

Artificial intelligence and automation are affecting both development paradigms, in different ways.

In CGT, AI and automation are being applied to de-risk specific manufacturing steps:

• Cell extraction, improving consistency in starting material collection
• Genetic modification, optimizing transduction or editing efficiency
• Expansion, monitoring and adjusting culture conditions in real time
• Purification, improving yield and removing impurities more reliably
• Formulation, standardizing final product preparation

These applications target the variability that makes CGT manufacturing so challenging. Closed, automated systems reduce manual handling, which lowers contamination risk and may improve batch-to-batch consistency.

Traditional drug discovery is changing in parallel. More than 173 AI-discovered drug programs were in clinical development as of early 2026, showing how computational methods are compressing target identification and compound optimization for small molecules.

The convergence raises a strategic question. If AI accelerates small-molecule discovery faster than automation resolves CGT manufacturing bottlenecks, the timeline and cost gap between the two paradigms may widen. If automation succeeds in making cell and vector production more predictable, the gap could narrow. Either outcome will shape how capital and partnerships are allocated across modalities.

Comparative Framework: CGT vs. Traditional Development, Stage by Stage

The table below summarizes the article’s findings as a side-by-side lifecycle comparison.

Each row is a separate decision point at which assumptions carried over from small-molecule work can mislead stakeholders.

Conclusion: Treating CGT as a Distinct Development Discipline

Cell and gene therapy is more than a new type of drug placed into an old development model. Its divergence is structural. It involves a different FDA review center, different trial architectures, manufacturing grounded in biology rather than chemistry, monitoring obligations that span more than a decade, and a commercial model built around one-time value.

The state of the field in 2026 reflects both progress and friction. The pipeline is growing, with biotech modalities now outnumbering small molecules. Regulatory frameworks are becoming more formal through coordinated FDA guidance. Manufacturing bottlenecks, particularly in viral vector capacity, persist. The funding rebound points to a cautious maturation, with investors rewarding execution over platform promises.

Stakeholders in BD, investment, manufacturing, and regulatory functions should apply a mental model built specifically for CGT. Adapting small-molecule assumptions tends to produce inaccurate timelines, underestimated costs, and flawed partnership decisions. Organizations that recognize CGT as its own development discipline are better placed to evaluate programs accurately in 2026.

Stay Ahead of the CGT Development Curve

Cell and gene therapy is changing quickly. Regulatory guidance, manufacturing approaches, and funding patterns are all shifting within short periods. Professionals who track these developments closely are better equipped to make sound diligence, partnership, and strategy decisions.

Readers are encouraged to:

• Share this framework with BD, regulatory, and investment colleagues to align internal discussions around modality-specific risk
• Return to this synthesis as a reference point as new approvals, guidances, and funding data emerge throughout 2026
• Subscribe for ongoing analysis of the trends shaping therapeutic development
• Reach out for deeper discussion on specific pipeline, regulatory, or partnership questions

Adiamed will continue to follow the structural shifts that separate cell and gene therapy from traditional drug development and to publish clear, well-sourced analysis for professionals working in the field.